In this study, patients are randomly assigned to the study groups (autologous peripheral blood, umbilical cord blood, autologous serum). Each patient, who wishes to undergo any treatment, has the right to be informed about their disease and the recommended treatment by the treating physician so that they can decide whether to proceed with it or not. During the study, you will need to complete an eye symptom assessment questionnaire (Ocular Surface Disease Index - OSDI).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Improvement of Dry Eye Disease parameters (Total Break-Up time)
Timeframe: From enrollment to the end of treatment at 4 weeks
Improvement of Dry Eye Disease parameters (Schirmer test)
Timeframe: From enrollment to the end of treatment at 4 weeks
Improvement of Dry Eye Disease parameters (Oxford Grading Scale)
Timeframe: From enrollment to the end of treatment at 4 weeks
Improvement of Dry Eye Disease parameters (Ocular Surface Disease Index-OSDI)
Timeframe: From enrollment to the end of treatment at 4 weeks